Health system intelligence profile
Mount Sinai Health System / Icahn School of Medicine at Mount Sinai
Editorially verified · Last reviewed August 30, 2026
Intelligence summary
Established 2018
Mount Sinai Innovation Partners (MSIP) is the commercialization organization for the Mount Sinai Health System and the Icahn School of Medicine, handling patenting, licensing, research partnerships and entrepreneurship. In 2018 the Icahn School of Medicine capitalized the i3 Asset Accelerator with an initial $10 million to fast-track commercially relevant discoveries toward patients using a milestone-based development strategy. The accelerator is guided by an advisory team of more than 40 scientists, business professionals and commercialization experts who both allocate funding and steer development. Early funded assets included a novel drug-development platform for cancer and therapies for influenza B. The combination gives Mount Sinai an internal capital vehicle for its own science rather than an external venture fund.
Documented successes: Erik Lium promoted to Executive Vice President of MSIP in 2018 after building the office's commercialization portfolio; MSIP maintains a venture/portfolio investment arm tracked by CB Insights; dedicated managing directors for business development, technology transactions/IP and strategic alliances; i3 Asset Accelerator launched in 2018 with an initial $10 million commitment; advisory team of more than 40 scientists and commercialization experts; first funded projects were a novel cancer drug-development platform led by Ross Cagan, PhD and Arvin Dar, PhD, and influenza B therapies led by Florian Krammer, PhD
Mandate and remit
Mount Sinai Innovation Partners (MSIP) is the commercialization organization for the Mount Sinai Health System and the Icahn School of Medicine, handling patenting, licensing, research partnerships and entrepreneurship. In 2018 the Icahn School of Medicine capitalized the i3 Asset Accelerator with an initial $10 million to fast-track commercially relevant discoveries toward patients using a milestone-based development strategy. The accelerator is guided by an advisory team of more than 40 scientists, business professionals and commercialization experts who both allocate funding and steer development. Early funded assets included a novel drug-development platform for cancer and therapies for influenza B. The combination gives Mount Sinai an internal capital vehicle for its own science rather than an external venture fund.
These routes appear in the program's sourced public record.
Fund or office: Mount Sinai Innovation Partners
Mount Sinai Innovation Partners (MSIP) is the commercialization organization for the Mount Sinai Health System and the Icahn School of Medicine, handling patenting, licensing, research partnerships and entrepreneurship. In 2018 the Icahn School of Medicine capitalized the i3 Asset Accelerator with an initial $10 million to fast-track commercially relevant discoveries toward patients using a milestone-based development strategy. The accelerator is guided by an advisory team of more than 40 scientists, business professionals and commercialization experts who both allocate funding and steer development. Early funded assets included a novel drug-development platform for cancer and therapies for influenza B. The combination gives Mount Sinai an internal capital vehicle for its own science rather than an external venture fund.
Documented successes
Erik Lium promoted to Executive Vice President of MSIP in 2018 after building the office's commercialization portfolio; MSIP maintains a venture/portfolio investment arm tracked by CB Insights; dedicated managing directors for business development, technology transactions/IP and strategic alliances; i3 Asset Accelerator launched in 2018 with an initial $10 million commitment; advisory team of more than 40 scientists and commercialization experts; first funded projects were a novel cancer drug-development platform led by Ross Cagan, PhD and Arvin Dar, PhD, and influenza B therapies led by Florian Krammer, PhD
Organizational home: Mount Sinai Innovation Partners, Mount Sinai Health System / Icahn School of Medicine at Mount Sinai
Use the program's published contact route for partnership, licensing, innovation, or program inquiries.
Comparable records based on shared public taxonomy, location, or commercialization route.
Same state · Same program type · Same commercialization route
Albany, New York
Office of Translational Research, Innovation, and Technology Transfer (OTR)
The Office of Translational Research, Innovation, and Technology Transfer supports Albany Medical College inventors in moving biomedical discoveries toward commercialization.
Academic · Nonprofit
Read the intelligence briefReviewed August 30, 2026
Same state · Same program type · Same commercialization route
New York, New York
Columbia Technology Ventures
Columbia Technology Ventures (CTV) is the technology transfer and commercialization office for Columbia University, including its medical center faculty and clinicians.
Academic · Nonprofit
Read the intelligence briefEditorially verified · Reviewed August 30, 2026
Same state · Same program type · Same commercialization route
Ithaca, New York
Center for Technology Licensing (CTL)
The Center for Technology Licensing is the commercialization arm of Cornell University, with a dedicated office serving Weill Cornell Medicine in New York City.
Academic · Nonprofit
Read the intelligence briefEditorially verified · Reviewed August 30, 2026
Same state · Same program type · Same commercialization route
New York, New York
HSS Innovation Institute
The HSS Innovation Institute develops and commercializes musculoskeletal healthcare technologies originating from Hospital for Special Surgery clinicians and researchers.
Nonprofit
Read the intelligence briefReviewed August 30, 2026
Same state · Same program type · Same commercialization route
New York, New York
Office of Entrepreneurship and Commercialization (OEC)
The Office of Entrepreneurship and Commercialization is Memorial Sloan Kettering's technology commercialization arm, renamed from the Office of Technology Development in October 2024.
Nonprofit
Read the intelligence briefReviewed August 30, 2026
Same state · Same program type · Same commercialization route
Bronx, New York
Office of Biotechnology and Business Development
The Office of Biotechnology and Business Development is the technology transfer and industry-partnering office for Albert Einstein College of Medicine within the Montefiore Einstein system.
Academic · Nonprofit
Read the intelligence briefReviewed August 30, 2026
Reviewed August 30, 2026. External source links open in a new tab.
Confidential comparison
Request a confidential conversation about the commercial opportunities, market pathways, and capabilities within your hospital's innovation portfolio. The public directory does not score or rank programs.